Agennix AG Appoints New Vice President of Clinical Development
News Apr 18, 2011
Agennix AG has announced the appointment of Steven Simonson, M.D., M.H.S. as Vice President, Clinical Development, reporting to Dr. Rajesh Malik, the Company's Chief Medical Officer. In this newly-created position, Dr. Simonson will lead the Company's sepsis development program with oral talactoferrin.
Rajesh Malik, M.D., Chief Medical Officer, said, "I am delighted to have Dr. Simonson join the team at Agennix. He has extensive clinical, academic and industry experience, including running a sepsis clinical development program at a major international pharmaceutical company. He joins us at a critical time as we prepare to initiate our Phase II/III trial with talactoferrin in severe sepsis."
Dr. Simonson has fifteen years of pharmaceutical industry experience. Prior to joining Agennix, Dr. Simonson held several senior positions at AstraZeneca, most recently as Senior Director, Clinical Research, Infection Therapeutic Area.
In this position, he served as the lead physician for a Phase II program in sepsis. Prior to his industry career, Dr. Simonson held several academic positions at Duke University Medical Center.
He received his M.D. from Medical College of Wisconsin and a Masters degree in Health Sciences from Duke University School of Medicine. He is Board certified in Pulmonary, Critical Care and Internal Medicine.
The Alzheimer drug candidate PRI-002 has successfully completed Phase I of clinical research involving healthy volunteers. When administered daily over a period of four weeks, the active substance proved to be safe for use in humans. The next milestone will be the proof of efficacy in patients in clinical Phase II.READ MORE